Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

14.72
-0.3100-2.06%
Pre-market: 14.720.00000.00%04:15 EDT
Volume:1.80M
Turnover:26.15M
Market Cap:1.18B
PE:-31.66
High:14.92
Open:14.75
Low:14.20
Close:15.03
52wk High:25.77
52wk Low:3.50
Shares:80.02M
Float Shares:57.22M
Volume Ratio:0.90
T/O Rate:3.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4650
EPS(LYR):-0.4650
ROE:-16.94%
ROA:-7.64%
PB:5.05
PE(LYR):-31.66

Loading ...

A Look At Monte Rosa Therapeutics (GLUE) Valuation After Its Recent Share Price Pullback

Simply Wall St.
·
Mar 21

J.P. Morgan Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Mar 19

Monte Rosa Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 18

Monte Rosa Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Mar 18

Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Mar 18

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires Live
·
Mar 17

Monte Rosa Therapeutics Inc. publishes corporate presentation on molecular glue degrader pipeline with three clinical programs

Reuters
·
Mar 17

Monte Rosa Q4 net loss widens 244% to USD 46.14 million on revenue down 95% to USD 2.78 million

Reuters
·
Mar 17

BRIEF-Monte Rosa Therapeutics Q4 Operating Income USD -49.715 Million

Reuters
·
Mar 17

Monte Rosa Therapeutics Q4 Net Income USD -46.135 Million

THOMSON REUTERS
·
Mar 17

Monte Rosa Therapeutics Q4 Operating Expenses USD 52.496 Million

THOMSON REUTERS
·
Mar 17

Press Release: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Dow Jones
·
Mar 17

BUZZ-U.S. STOCKS ON THE MOVE-Customers Bancorp, Forgent Power Solutions, Nvidia

Reuters
·
Mar 17

BUZZ-U.S. STOCKS ON THE MOVE-Dollar Tree, Micron, Customers Bancorp

Reuters
·
Mar 16

Monte Rosa Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
Mar 16

Monte Rosa Therapeutics Announces Clinical Supply Agreement To Support Phase 2 Trial Evaluating Mrt-2359 In Combination With Apalutamide For The Treatment Of Metastatic Castration-Resistant Pros

Reuters
·
Mar 16

BUZZ-U.S. STOCKS ON THE MOVE-Sable Offshore, Nebius, Upstart

Reuters
·
Mar 16

BUZZ-Monte Rosa rises on lining up new combo trial in advanced prostate cancer

Reuters
·
Mar 16

Monte Rosa to launch Phase 2 trial of MRT-2359 plus apalutamide in AR-mutant mCRPC in Q3 2026

Reuters
·
Mar 16

Monte Rosa Therapeutics Inc - to Conduct and Sponsor Trial; Johnson & Johnson to Supply Erleada

THOMSON REUTERS
·
Mar 16